Sickle Cell Outcomes, Policy and Excellence

Add to Calendar Sickle Cell Outcomes, Policy and Excellence 8/14/2025 8:00:00 AM 8/14/2025 4:00:00 PM America/Chicago For More Details: https://TC.cloud-cme.com/course/courseoverview?EID=31170 Description: Sickle cell disease (SCD) affects millions of people worldwide including over 100,000 in the United States. Clinical manifestations of SCD include anemia, severe recurrent pain, strokes, and over time, damage to every organ in the body, resulting in premature death. Yet, despite its prevalence, devastating clinical effects, and significant impact on the healthcare system, healthcare inequities have delaye... Jan and Dan Duncan Neurological Research Institute (NRI) Conference Center false MM/DD/YYYY


Date & Location
Thursday, August 14, 2025, 8:00 AM - 4:00 PM, Jan and Dan Duncan Neurological Research Institute (NRI) Conference Center, Houston, TX

Target Audience
Specialties - Academic/Research, Anesthesiology, Behavioral Health, Chaplains, Critical Care Medicine, Dental, Department of Obstetrics and Gynecology, Department of Pediatric Radiology, Department of Surgery, General Surgery, Hematology, Obstetrics, Pediatric Radiology
Professions - Administrative Research Staff, Administrative Staff, Advanced Practice Provider, Allied Health Professional, Certified Registered Nurse Anesthetist, Chaplain, Child Life, Dentist, Doctor of Osteopathic Medicine, Emergency Medical Technician, Fellow, MBBS, Medical Assistant, Non-Clinical Professional, Non-Physician, Nurse, Nurse Midwife, Nurse Practitioner, Occupational Therapist, Pharmacist, Pharmacy Technician, Physical Therapist, Physician, Physician Assistant, Psychiatrist, Psychological Therapist, Resident, Respiratory Therapist, School Nurse, Social Worker, Spiritual Care, Student

Credits
AMA PRA Category 1 Credits™ (4.00 hours), CEU (4.00 hours), Contact Hours (ANCC) (4.00 hours), General Attendance (4.00 hours), Non-Physician Attendance (4.00 hours)

Overview
Sickle cell disease (SCD) affects millions of people worldwide including over 100,000 in the United States. Clinical manifestations of SCD include anemia, severe recurrent pain, strokes, and over time, damage to every organ in the body, resulting in premature death. Yet, despite its prevalence, devastating clinical effects, and significant impact on the healthcare system, healthcare inequities have delayed progress in improving and extending the quality of life for affected individuals. Over the last 10 years, innovative SCD research has gained ground, expanding how scientists conceive of the disease. After a gap of nearly 20 years, advancements in pharmaceutical development have led to the approval of new therapies. Curative therapies have also entered the discussion with the recent success of alternative donor transplants and approval of gene therapy. Efforts to promote hematology training hold promise to increase the number of skilled healthcare professionals treating these patients. This long-awaited progress requires careful planning and implementation across broad healthcare stakeholders to successfully reach and ultimately improve the experience of those living with SCD. The proposed symposium will build on the success of a statewide initiative and broaden the discussion to a national audience. This event will bring together key leaders across the field of SCD to discuss the implementation and impact of novel interventions, to define critical outcomes and metrics of successful care delivery to patients, and to develop policy initiatives to promote equitable access to healthcare for members of the entire sickle cell community. Objectives: • Evaluate available and forthcoming therapies for SCD with emphasis on access for the relevant populations within the sickle cell community who would most benefit. • Identify, measure, and track key outcomes and metrics reflective of optimal SCD care. • Develop and advance policy initiatives to address gaps in access to care and the equitable provision of resources for patients with SCD.

ACCME Objectives
  1. Evaluate available and forthcoming therapies for SCD with emphasis on access for the relevant populations within the sickle cell community who would most benefit.
  2. Identify, measure, and track key outcomes and metrics reflective of optimal SCD care.
  3. Develop and advance policy initiatives to address gaps in access to care and the equitable provision of resources for patients with SCD.

ANCC Learning Outcomes
  1. At the conclusion of this activity, 90% of respondents will identify at least one concept learned to enhance equitable and high-quality care for patients with Sickle Cell Disease.

Registration

Travel Assistance:

If interested in assistance, please contact Rebecca Ulloa at [email protected]. Each inquiry will be reviewed individually for tailored support.


Accreditation

Texas Children’s Hospital is accredited by the Texas Medical Association to provide continuing medical education for physicians. Texas Children’s Hospital designates this Live Activity activity for a maximum of 4.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Texas Children’s Hospital is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This nursing continuing professional development (NCPD) activity awards up to 4.0 contact hours.


Additional Information

Accessibility Statement
 
Texas Children's Hospital is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.